Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Aging Dis ; 10(2): 278-292, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31011479

RESUMO

The identification of more reliable diagnostic or prognostic biomarkers in age-related neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), is urgently needed. The objective in this study was to identify more reliable prognostic biomarkers of ALS mirroring neurodegeneration that could be of help in clinical trials. A total of 268 participants from three cohorts were included in this study. The muscle and blood cohorts were analyzed in two cross-sectional studies, while the serial blood cohort was analyzed in a longitudinal study at 6-monthly intervals. Fifteen target genes and fourteen proteins involved in muscle physiology and differentiation, metabolic processes and neuromuscular junction dismantlement were studied in the three cohorts. In the muscle biopsy cohort, the risk for a higher mortality in an ALS patient that showed high Collagen type XIX, alpha 1 (COL19A1) protein levels and a fast progression of the disease was 70.5% (P < 0.05), while in the blood cohort, this risk was 20% (P < 0.01). In the serial blood cohort, the linear mixed model analysis showed a significant association between increasing COL19A1 gene levels along disease progression and a faster progression during the follow-up period of 24 months (P < 0.05). Additionally, higher COL19A1 levels and a faster progression increased 17.9% the mortality risk (P < 0.01). We provide new evidence that COL19A1 can be considered a prognostic biomarker that could help the selection of homogeneous groups of patients for upcoming clinical trial and may be pointed out as a promising therapeutic target in ALS.

2.
Rev Chilena Infectol ; 30(2): 156-61, 2013 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-23677154

RESUMO

INTRODUCTION: The development of malignancies is a problem associated with HIV infection. The incidence and spectrum of malignancies has been modified with the addition of highly active antiretroviral therapy (HAART). AIM: To describe the clinical and epidemiological characteristics and prognosis of HIV patients who have developed a malignancy. METHODS: Retrospective observational study was conducted in HIV + patients who developed a malignancy between 1993-2010 in a referral hospital. AIDS-defining malignancies (ADN) and non-AIDS-defining malignancies (NADN) were compared. RESULTS: 125 patients were identified with at least one malignancy. The most frequent malignancies were: non-Hodgkin lymphoma (n; 39; 30.2%), Kaposi's sarcoma (n: 20; 15.5%), Hodgkin's disease (n: 11; 8.8%), lung cancer (n: 20; 15.5%) and hepatocellular carcinoma (n: 9; 6.9 %). The mean age was 42 ± 11 years, 84% male, 55.8% were coinfected with HBV and or HCV. The risk behaviors were: 45.6% intravenous drug users, 16.8% men who have sex with men and 20% heterosexuals). There were 67 (52%) NADN and 62 (48%) ADN; NADN patients had a longer story of HIV infection and longer exposure to HAART, better level of immunodeficiency and better virological control than ADN patients. Four patients developed a second malignancy. Overall survival was 34.7%. CONCLUSIONS: We found an increased incidence of NADN, appearing in patients with better virological and immunological control than ADN group. Mortality of patients with HIV infection and malignancy is still very high.


Assuntos
Infecções por HIV/complicações , Neoplasias/etiologia , Adulto , Terapia Antirretroviral de Alta Atividade , Contagem de Linfócito CD4 , Estudos de Coortes , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Prognóstico , Estudos Retrospectivos , Espanha/epidemiologia , Análise de Sobrevida
3.
Rev. chil. infectol ; 30(2): 156-161, abr. 2013. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-673997

RESUMO

Introduction: The development of malignancies is a problem associated with HIV infection. The incidence and spectrum of malignancies has been modified with the addition of highly active antiretroviral therapy (HAART). Aim: To describe the clinical and epidemiological characteristics and prognosis of HIV patients who have developed a malignancy. Methods: Retrospective observational study was conducted in HIV + patients who developed a malignancy between 1993-2010 in a referral hospital. AIDS-defining malignancies (ADN) and non-AIDS-defining malignancies (NADN) were compared. Results: 125 patients were identified with at least one malignancy. The most frequent malignancies were: non-Hodgkin lymphoma (n; 39; 30.2%), Kaposi's sarcoma (n: 20; 15.5%), Hodgkin's disease (n: 11; 8.8%), lung cancer (n: 20; 15.5%) and hepatocellular carcinoma (n: 9; 6.9 %). The mean age was 42 ± 11 years, 84% male, 55.8% were coinfected with HBV and or HCV. The risk behaviors were: 45.6% intravenous drug users, 16.8% men who have sex with men and 20% heterosexuals). There were 67 (52%) NADN and 62 (48%) ADN; NADN patients had a longer story of HIV infection and longer exposure to HAART, better level of immunodeficiency and better virological control than ADN patients. Four patients developed a second malignancy. Overall survival was 34.7%. Conclusions: We found an increased incidence of NADN, appearing in patients with better virological and immunological control than ADN group. Mortality of patients with HIV infection and malignancy is still very high.


Introducción: Uno de los problemas asociados a la infección por VIH es el desarrollo de neoplasias. La incidencia y espectro de los distintos cánceres se ha visto modificada con la incorporación del tratamiento anti-retroviral de gran actividad (TARGA). El objetivo del presente estudio es describir las características clínicas y epidemiológicas y el pronóstico de pacientes infectados con VIH que han desarrollado una neoplasia. Material y Métodos: Estudio observacional retrospectivo de una cohorte de pacientes con infección por VIH que desarrollaron algún cáncer en el periodo comprendido entre 1993-2010 en un hospital de referencia. Se compararon las variables entre los casos de neoplasias definitorias de SIDA (NDS) y no definitorios de SIDA (NNDS). Resultados: Se identificaron 125 pacientes con al menos una neoplasia. Los cánceres más frecuentes fueron: linfoma no Hodgkin (n: 39; 30,2%), sarcoma de Kaposi (n: 20; 15,5%), enfermedad de Hodgkin (n: 11; 8,8%), neoplasia pulmón (n: 20; 16%) y hepatocarcinoma (n: 9; 6,9 %). La edad media fue 42 ± 11 años, 84% varones, 55,8% estaban co-infectados por VHB y/o VHC. Las conductas de riesgo fueron: 45,6% usuarios de drogas vía parenteral, 16,8% hombres con relaciones sexuales con hombres y 20% heterosexuales. Se encontraron 67 NNDS (52%) y 62 (48%) NDS; los pacientes con NNDS presentaron mayor tiempo de evolución de la infección por VIH y de exposición a TARGA, mayor recuento de CD4 y mejor control virológico que los del grupo de NDS. Desarrollaron un segundo tumor cuatro pacientes. La supervivencia global fue de 34,7%. Conclusiones: Se constata un aumento en la incidencia de NNDS, que se presentan en pacientes con mejor control virológico e in-munológico que los NDS. La mortalidad de los pacientes con infección por VIH y enfermedad tumoral continúa siendo muy elevada.


Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infecções por HIV/complicações , Neoplasias/etiologia , Terapia Antirretroviral de Alta Atividade , Estudos de Coortes , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Neoplasias/epidemiologia , Prognóstico , Estudos Retrospectivos , Análise de Sobrevida , Espanha/epidemiologia
4.
Int J Radiat Oncol Biol Phys ; 84(5): 1151-8, 2012 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-22516806

RESUMO

PURPOSE: Management of locally advanced rectal cancer (RC) consists of neoadjuvant chemoradiotherapy (CRT) with fluoropyrimidines, followed by total mesorectal excision. We sought to evaluate the expression of selected genes, some of which were derived from a previous undirected SAGE (serial analysis of gene expression)-based approach, before and after CRT, to identify mechanisms of resistance. METHODS: This retrospective cohort study included 129 consecutive patients. Quantitative polymerase chain reaction of 53 candidate genes was performed on the biopsy specimen before treatment and on the surgical specimen after CRT. A paired-samples t test was performed to determine genes that were significantly changed after CRT. The result was correlated with patients' disease-free survival. RESULTS: Twenty-two genes were significantly upregulated, and two were significantly downregulated. Several of the upregulated genes have roles in cell cycle control; these include CCNB1IP1, RCC1, EEF2, CDKN1, TFF3, and BCL2. The upregulation of TFF3 was associated with worse disease-free survival on multivariate analyses (hazard ratio, 2.64; P=.027). Patients whose surgical specimens immunohistochemically showed secretion of TFF3 into the lumen of the tumoral microglands had a higher risk of relapse (hazard ratio, 2.51; P=.014). In vitro experiments showed that DLD-1 cells stably transfected with TFF3 were significantly less sensitive to 5-fluorouracil and showed upregulation of genes involved in the transcriptional machinery and in resistance to apoptosis. CONCLUSION: Upregulation of TFF3 after CRT for RC is associated with a higher risk of relapse. The physiological role of TFF3 in restoring the mucosa during CRT could be interfering with treatment efficacy. Our results could reveal not only a novel RC prognostic marker but also a therapeutic target.


Assuntos
Adenocarcinoma/metabolismo , Quimiorradioterapia Adjuvante , Proteínas de Neoplasias/metabolismo , Recidiva Local de Neoplasia , Peptídeos/metabolismo , Neoplasias Retais/metabolismo , Neoplasias Retais/terapia , Adenocarcinoma/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linhagem Celular Tumoral , Quimiorradioterapia Adjuvante/métodos , Intervalo Livre de Doença , Resistencia a Medicamentos Antineoplásicos/genética , Feminino , Perfilação da Expressão Gênica/métodos , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Proteínas de Neoplasias/genética , Peptídeos/genética , Reação em Cadeia da Polimerase , Prognóstico , Análise Serial de Proteínas/métodos , Neoplasias Retais/genética , Estudos Retrospectivos , Transfecção/métodos , Fator Trefoil-3 , Regulação para Cima , Adulto Jovem
5.
PLoS One ; 7(3): e32632, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22412900

RESUMO

The pathophysiological mechanisms of both familial and sporadic Amyotrophic Lateral Sclerosis (ALS) are unknown, although growing evidence suggests that skeletal muscle tissue is a primary target of ALS toxicity. Skeletal muscle biopsies were performed on transgenic SOD1(G93A) mice, a mouse model of ALS, to determine genetic biomarkers of disease longevity. Mice were anesthetized with isoflurane, and three biopsy samples were obtained per animal at the three main stages of the disease. Transcriptional expression levels of seventeen genes, Ankrd1, Calm1, Col19a1, Fbxo32, Gsr, Impa1, Mef2c, Mt2, Myf5, Myod1, Myog, Nnt, Nogo A, Pax7, Rrad, Sln and Snx10, were tested in each muscle biopsy sample. Total RNA was extracted using TRIzol Reagent according to the manufacturer's protocol, and variations in gene expression were assayed by real-time PCR for all of the samples. The Pearson correlation coefficient was used to determine the linear correlation between transcriptional expression levels throughout disease progression and longevity. Consistent with the results obtained from total skeletal muscle of transgenic SOD1(G93A) mice and 74-day-old denervated mice, five genes (Mef2c, Gsr, Col19a1, Calm1 and Snx10) could be considered potential genetic biomarkers of longevity in transgenic SOD1(G93A) mice. These results are important because they may lead to the exploration of previously unexamined tissues in the search for new disease biomarkers and even to the application of these findings in human studies.


Assuntos
Esclerose Lateral Amiotrófica/genética , Proteínas Mutantes/genética , Superóxido Dismutase/genética , Animais , Biópsia , Denervação , Modelos Animais de Doenças , Progressão da Doença , Feminino , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Marcadores Genéticos , Humanos , Longevidade/genética , Masculino , Camundongos , Camundongos Transgênicos , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Superóxido Dismutase-1 , Transcrição Gênica
7.
J Periodontol ; 75(10): 1413-6, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15562920

RESUMO

BACKGROUND: This report describes the surgical treatment of a gingival recession in a hemophiliac HIV-infected patient. To our knowledge, mucogingival surgery has not been described previously in these patients. METHODS: Under the supervision of the patient's hematologist, a subepithelial connective tissue graft procedure was carried out to treat the recession. The treatment was performed after substitution therapy with factor VIII concentrate, supported by local antifibrinolytic treatment with epsilonaminocaproic acid. RESULTS: One week after surgery, the grafted zone showed a normal healing, but an area of necrosis appeared at the donor palatal site with spontaneous bleeding. The administration of factor VIII concentrate had to be prolonged to arrest the hemorrhage. In total, 44,500 units of factor VIII concentrate were used, the cost of which reached around $20,000. After 1 month the donor site had re-epithelialized by secondary intention. The root coverage was around 85% successful. CONCLUSIONS: Because of the surgical risk and the high economic cost in the use of the factor VIII concentrate, we do not recommend performing mucogingival surgery in HIV-infected hemophiliacs unless it is absolutely necessary. Prevention and early treatment must be the goal in the management of these patients.


Assuntos
Retração Gengival/cirurgia , Infecções por HIV/complicações , Hemofilia A/complicações , Adulto , Ácido Aminocaproico/uso terapêutico , Antifibrinolíticos/uso terapêutico , Coagulantes/economia , Coagulantes/uso terapêutico , Tecido Conjuntivo/transplante , Custos de Medicamentos , Fator VIII/economia , Fator VIII/uso terapêutico , Gengiva/transplante , Retração Gengival/economia , Sobrevivência de Enxerto , Hemofilia A/economia , Humanos , Masculino , Necrose , Hemorragia Bucal/etiologia , Hemorragia Pós-Operatória/etiologia
8.
Rev. invest. clín ; 52(3): 255-60, mayo-jun. 2000. tab, graf, CD-ROM
Artigo em Espanhol | LILACS | ID: lil-292130

RESUMO

Las cisteín-proteasas de Entamoeba histolytica son consideradas factores de virulencia importantes en la patogénesis de la amibiasis. Con base en la diferencia que presenta el gene enhhic que codifica para una proteasa de 30 kDa, en este trabajo se validó una estrategia para diferenciar Entamoeba histolytica patógena de la no patógena por medio del patrón de restricción. Material y métodos. Se utilizaron 13 muestras de materia fecal con quistes de Entamoeba histolytica aislados de cuatro individuos asintomáticos y nueve sintomáticos de diferentes edades, sexos y se cultivaron en medio de Robinson. A partir del DNA extraído de los trofozoítos se amplificó el gene enhhic por PCR y se cortó con las enzimas de restricción Taq I y Hinf I. Resultados. De todos los aislados cultivados en medio de Robinson, se obtuvo un fragmento amplificado de 530 pb que hibridó con una sonda para Entamoeba histolytica. Sin embargo la evaluación por digestión enzimática con Taq I y Hinf I indicó que sólo dos de las cuatro muestras que pertenecían a individuos asintomáticos correspondían a poblaciones patógenas de acuerdo al patrón de restricción de la cepa control HM-I:IMSS, las nueve restantes correspondientes a pacientes sintomáticos presentaron un patrón de restricción semejante a la cepa patógena. Conclusiones. Estos resultados muestran que la amplificación del gene enhhic por la reacción en cadena de la polimerasa no es suficiente para establecer un diagnóstico diferencial. Para considerar que una cepa es patógena es necesario realizar digestión enzimática.


Assuntos
Cisteína Endopeptidases/farmacocinética , Entamoeba histolytica/patogenicidade , Genes , Técnicas In Vitro , Mapeamento por Restrição , Fezes/microbiologia , Reação em Cadeia da Polimerase
9.
Rev. invest. clín ; 49(2): 123-8, mar.-abr. 1997. ilus
Artigo em Espanhol | LILACS | ID: lil-219670

RESUMO

Mediante separación isoeléctrica y reisoelectroenfoque se obtuvieron las proteínas de citoesqueleto de Giardia intestinalis con características de giardinas y tubulinas, constituyentes principales del disco ventral. El peso molecular fue 30 a 45 kDa así como las de sus variantes determinadas por la diferencia de pH. Además de las mismas se obtuvieron predominantemente polipéptidos de peso molecular de 97 y 115 kDa. Por inmunocitoquímica se demostró que estas proteínas de peso molecular elevado se localizaron sobre la membrana del trofozoíto, y en menor proporción se observaron proteínas con pesos moleculares semejantes a los de giardinas y tubulinas


Assuntos
Animais , Imunofluorescência , Giardia lamblia/química , Giardia lamblia/crescimento & desenvolvimento , Giardia lamblia/ultraestrutura , Concentração de Íons de Hidrogênio , Técnicas Imunoenzimáticas , Focalização Isoelétrica , Peso Molecular , Proteínas do Citoesqueleto/isolamento & purificação , Proteínas de Membrana/isolamento & purificação , Proteínas de Protozoários/isolamento & purificação , Tubulinos/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA